Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Table 4 Scenario analyses results for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence

Scenario	Incremental cost per QALY gained (% change from base case)
Base case	€ 4099
Resistance adjustments
No adjustments	€ 11,461 (+ 180%)
Second-line efficacy
Assumed 100% response/cure rates in treatment	€ 4060 (− 1%)

CAZ-AVI = ceftazidime-avibactam; QALY = quality-adjusted life year.
CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem. Ceftolozane/tazobactam sequence: Ceftolozane/tazobactam, followed by colistin + tigecycline + high-dose meropenem

ISSN: 2047-2994